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Abstract
Background: Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for
Helicobacter pylori (HP) infection, but it has not been analysed as a second-line treatment. Therefore, we seek to
compare the effectiveness of a treatment regimen including rifabutin versus conventional quadruple therapy (QT).
Methods: Open clinical trial, randomised and multi-centre, of two treatment protocols: A) Conventional regime -QT-
(omeprazole 20 mg bid, bismuth citrate 120 mg qid, tetracycline 500 mg qid and metronidazole 500 mg tid); B)
Experimental one -OAR- (omeprazole 20 mg bid, amoxicillin 1 gr bid, and rifabutin 150 mg bid), both taken orally for 7
days, in patients with HP infection for whom first-line treatment had failed. Eradication was determined by Urea Breath
Test (UBT). Safety was determined by the adverse events.
Results: 99 patients were randomised, QT, n = 54; OAR, n = 45. The two groups were homogeneous. In 8 cases,
treatment was suspended (6 in QT and 2 in OAR). The eradication achieved, analysed by ITT, was for QT, 38 cases
(70.4%), and for OAR, 20 cases (44.4%); p = 0.009, OR = 1.58. Of the cases analysed PP, QT were 77.1%; OAR, 46.5%;
p = 0.002. Adverse effects were described in 64% of the QT patients and in 44% of the OAR patients (p = 0.04).
Conclusion: A 7-day rifabutin-based triple therapy associated to amoxicillin and omeprazole at standard dose was not
found to be effective as a second-line rescue therapy. The problem with quadruple therapy lies in the adverse side effects
it provokes. We believe the search should continue for alternatives that are more comfortably administered and that are
at least as effective, but with fewer adverse side effects.
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Background
Helicobacter pylori infection plays an important role in
the phatogenesis of chronic gastritis, gastroduodenal
ulcer, maltoma and gastric adenocarcinoma. First-line
treatment with triple therapy (proton pump inhibitor
(PPI)- associated with clarithromycin and amoxicillin or
metronidazole) is widely accepted and applied [1,2] and
has an effectiveness rate of almost 80%. Nevertheless, a
considerable proportion of patients fail to respond to the
latter treatment, and for these there is no ideal treatment
[3,4]. Quadruptherapy (PPI – associated with bismuth cit-
rate, tetracycline and metronidazole) is the most com-
monly used second-line treatment, with an eradication
rate of 57–95% [4-7]. However, this is not totally satisfac-
tory, due to the complexity of the dosing regimen and the
frequency of associated side effects [8]. Thus, alternative
options to be applied must be more effective, simpler and
better tolerated than the quadruple therapy.
In recent years, it has been shown that some antibiotics
can be useful in such circumstances. One of these is rifab-
utin: derived from rifampicin, it is used as a rescue treat-
ment against mycobacterium tuberculosis and as a
prophylactic against the mycobacterium avium intracellu-
lare infection of HIV-positive patients. It has been shown
to be effective in eradicating HP [9,10]. In relation to this
latter effect, it is very effective in vitro [11-13], achieving
lower levels of minimum inhibitory concentration than
obtained by clarithromycin and amoxicillin [14]. Moreo-
ver, its effectiveness does not depend on the pH of the
medium [15].
Many features make rifabutin-based therapy an interest-
ing alternative for clinical application to achieve the erad-
ication of HP. Firstly, it is effective at low doses [16] (300
mg), and so its side effects are minimised [17]. Secondly,
the primary resistance of HP to rifabutin in the popula-
tion at large is non-existent, because this antibiotic is only
used for very specific clinical situations [11,18]. Finally, its
efficacy is not reduced by the resistance that HP may
develop to other antibiotics, especially clarithromycin
and metronidazole [16,18,26], and so it can be adminis-
tered as a rescue treatment without the need for a prior
antibiogram.
Rifabutin-based therapy has been applied as a rescue treat-
ment for patients for whom one or more other treatments
have failed, i.e. as a rescue regimen for difficult to treat
patients [16,10,19,20,26]. No study of it has been made
as a second-line treatment, among a homogeneous group
of patients for whom a single eradication treatment of tri-
ple therapy with IBP, clarithromycin and amoxicillin/met-
ronidazole has failed.
To examine the hypothesis that a regimen including rifab-
utin may be as effective as one based on quadruple ther-
apy as a rescue treatment, and moreover, that it may
achieve higher levels of clinical tolerance, we designed a
multicentre, randomised, open clinical trial, with the par-
ticipation of five hospitals in southern Spain.
Methods
Study Design
This study was performed in acordance with the declara-
tion of Helsinki, and was approved by the Clinical Trials
Committee of the Autonomous Administration of Anda-
lucía, and by the corresponding committee of Hospital
Costa del Sol (Marbella), Hospital de Motril (Granada),
Hospital de Especialidades (Jaen), Hospital de Valme
(Sevilla) and Hospital Valle de los Pedroches
(Pozoblanco).
Patients were allocated to one of the following treatment
regimens: A) OAR (Omeprazole 20 mg/12 h, Amoxicillin
1 gr/12 h, Rifabutin 150 mg/12 h); and B) QT (Omepra-
zole 20 mg/12 h, Bismuth Citrate 120 mg/6 h, Tetracy-
cline 500 mg/6 h, and Metronidazole 500 mg/8 h). In
both cases, the medicaments were administered orally, for
7 days. Patients were progressively included in the trial as
determined by the application of a random number table,
with an entry number that was unknown to both research-
ers and patients. All patients signed a written informed
consent form. The medication provided was not masked,
because the main aim of the trial is influenced by adher-
ence to the treatment regimen, which in turn is affected by
the ease, or otherwise, with which the treatment is admin-
istered. The medication was prepared by the pharmaceuti-
cal service of the organising healthcare provider, delivered
in a sealed package, with the number of capsules necessary
for each group, and distributed to each participating hos-
pital. Each patient included in the study received a clinical
examination (or replied to a telephone interview) to iden-
tify the side effects caused by the treatment, following a
standardised protocol [21]. At 45 days after ending the
treatment, a secondary medical review was performed, at
which eradication of HP was determined by UBT and,
again, side effects were identified. At this moment, surplus
medication was returned. Consumption by the patient of
less than 90% of the capsules initially provided was eval-
uated as non-fulfilment of the recommended therapy. The
patient was classified as having withdrawn from the study
if follow up was not performed.
Inclusion and exclusion criteria
Patients in whom Helicobacter pylori infection persisted
after a triple therapy treatment were included. Persistence
of infection was determined by a breath test, by a rapid
urease test, by pathological anatomy or by culture. The
initial diagnosis of Helicobacter pylori infection wasBMC Gastroenterology 2007, 7:31 http://www.biomedcentral.com/1471-230X/7/31
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made by invasive methods (rapid ureasa test and/or path-
ological anatomy and/or Helicobacter culture) or by non-
invasive ones, i.e. a urea breath test decided upon after
infrared spectrophotometry or mass-spectrometry. All the
patients were given an initial endoscopy prior to the first
attempt at eradicating the infection. Patients were
excluded from the trial if they withheld consent, if they
had initially been treated by the "Test and Treat" proce-
dure or if a baseline endoscopy was not obtained. Also
excluded were those patients for whom fulfilment of the
treatment regimen and attendance at follow-up appoint-
ments could not reasonably be expected. Other condi-
tions for exclusion were HIV positive status, active
alcoholism, addiction to drugs, age less than 18 years or
more than 75 years, the suspicion of tuberculous infec-
tion, either because of a positive intradermal reaction to
Mantoux and compatible thorax radiography, or if the
patient had previously received tuberculostatic treatment,
or a known allergy to any of the components of either of
the two treatment regimens. Patients who had received
quadruple therapy as first-line treatment, or any other
treatment including bismuth (e.g., ranitidine bismuth cit-
rate), or antibiotics during the previous month, were
excluded from the trial. In addition, patients with severe
associated diseases (cardiac insufficiency, respiratory
insufficiency, chronic kidney insufficiency, hepatic insuf-
ficiency, advanced neoplasic diseases), as well as those
who were pregnant or lactating, were excluded.
Principal variable
Eradication was defined as having occurred when a nega-
tive UBT result was recorded, with urea marked with 13-C,
at 45 days after finalising the treatment. A minimum of 15
days of suspension of any proton pump inhibitor was
required, and a similar period of abstinence from antibi-
otics before the UBT. The test was carried out by personnel
who were unaware of the medication taken by the patient,
using the infrared spectrophotometry procedure, which
has a diagnostic efficacy similar to that obtained by mass
spectrophotometry [22,23] (UbiT -IR 300 – Otsuka Elec-
tronics Co., Ltd). The results were considered to be nega-
tive when the ratio obtained between the baseline sample
and that obtained after the administration of urea marked
with 13-C was ≤ 2.5 0/00 and positive if this value was
higher than 2.5 0/00. The analysis of efficacy was planned:
a) by intention to treat (ITT), on all the patients included
in the trial (in the case of loss of follow up, this was con-
sidered a positive result in the experimental group and a
negative one in the quadruple therapy following the
worse case method); b) per protocol (PP), which included
only the patients who had completed the whole follow up
procedure and had consumed at least 90% of the medica-
tion provided.
Secondary variable
Adverse side effects were recorded on a purpose-made
form, at 7 and 45 days after finalising the treatment. Such
effects were considered mild if they were well tolerated by
the patient, moderate if they were of sufficient intensity as
to interfere with the patient's normal life or as to require
medical intervention, serious when they impeded the per-
formance of everyday activities, significantly affected the
clinical situation and justified medical intervention, and
acute when the patient's life was put at risk.
Sample size
The sample size was calculated according to a forecast
eradication rate of 67% with the QT (based on the values
obtained in preliminary studies at our Hospital, unpub-
lished data) and on a forecast success rate of 84% for OAR,
with a level of significance of 0.05 and a power of 0.80.
We foresaw a minimum number of 102 patients per
group, this figure including a 10% oversizing element.
The trial was designed in the expectation of an intermedi-
ate analysis when half of the calculated sample size had
been achieved; the trial would be interrupted if a differ-
ence equal to or greater than 30% determined by ITT was
found, if such a difference were statistically significant.
Statistical analysis
A descriptive statistical analysis was carried out, with
measures of central trend and dispersion for the continu-
ous variables, and frequency distribution for the qualita-
tive variables, comparing the baseline levels of the two
groups of patients for the membership variables (age and
sex) and clinical variables (type of endoscopic injury,
tobacco consumption, defined as smoking 10 or more cig-
arettes per day). We compared the rate of eradication in
each treatment group, using the odds ratio (OR) of inci-
dence, and the chi squared test was used against the
hypothesis. A multivariate logistic regression model was
built adjusting for basal variables. The level of statistical
significance was established as p < 0.05.
Results
Patients were included in the study from September 2004
until August 2005, and an intermediate analysis was per-
formed (from which definitive results were obtained)
when half of the initially scheduled sample had been
examined. Figure 1 shows that of a total of 102 patients,
three were excluded.
Of the 99 patients definitively included, 45 were assigned
to Group A (OAR) and 54 to Group B (QT). Table 1 shows
that the groups were homogeneous with regard to sex, age,
tobacco consumption and endoscopic injury. Although
there was a higher proportion of ulcerous patients in the
QT group, this difference was not statistically significant.BMC Gastroenterology 2007, 7:31 http://www.biomedcentral.com/1471-230X/7/31
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The QT group presented a higher consumption of
NSAIDs.
Table 2 illustrates the efficacy of the two treatments. By
intention to treat (ITT), in the QT group, HP was eradi-
cated in 38 of the 54 patients (70.4%), while the OAR
treatment only eradicated it in 20 of the 45 cases (44.4%);
the difference was statistically significant (p = 0.009; OR =
1.58). In the per protocol (PP) analysis, similar differ-
ences were observed: a cure was achieved in 37 of the 48
patients who completed the treatment (77%), and in 20
of the 43 who finalised the OAR programme (45%); this
difference was also statistically significant (p = 0.002).
One patient in the QT group achieved HP eradication
despite not having completed the course of treatment. The
adjustment for the basal variables in the model of logistic
regression did not modify these results (data not shown).
We analysed the efficacy achieved with respect to the
endoscopic injury and no differences were found in erad-
ication rates between ulcerous (56.8% of 44 cases) and
nonulcerous patients (57.7%).
The treatment was not completed in 8 cases: 6 in the QT
group because of unacceptable side effects (UBT control
was achieved in all), and 2 in the OAR group, because of
loss of follow up.
Table 3 shows the adverse events recorded. In the QT
group 35 patients (64%) reported at least one adverse
event, versus 44% of the patients in the OAR group (p =
0.042). The most commonly described such events were
epigastralgia and/or dyspepsia, taste loss or variation, diz-
ziness, diarrhoea, nausea and/or vomiting, loss of appe-
tite and cephalea. Severe effects were much less frequent.
No leucopoenia was found. 14 events were classified as
severe; of these, 11 were in the QT group and 3 in the OAR
group. No patient in the latter group stopped medication
for this reason.
Discussion
A controlled study was carried out to compare a quadru-
ple therapy and an experimental one with rifabutin (asso-
ciated with omeprazole and amoxicillin), as second-line
treatment. The efficacy obtained with the rifabutin regi-
men was 44% (ITT) and 45% (PP), greatly inferior to that
obtained with the quadruple therapy (70% and 76%,
respectively).
HP infection is not easy to eradicate when the first-line
treatment fails. The most important predictors of failure
are antibiotics resistance and regimen compliance. Quad-
ruple therapy has an estimated efficacy of about 75% [24],
Table 1: Demographic data of the patients.
QT (n = 54) OAR (n = 45) P value
Age 46.4 48.6 ns
Sex (male/female) 25/29 23/22 ns
Caucasian 96.3% 97.7%
Endoscopic findings
Chronic gastritis 25 (46.3%) 28 (62.2%)
GD Ulcer 29 (53.7%) 17 (37.8%) ns
Smokers 12 (22.2%) 10 (22.2%) ns
Alcohol consumers 15 (27.8%) 11 (24.4%) ns
ASA/NSAID 10 (18.5%) 2 (4.4%) 0.031
GD Ulcer: Gastroduodenal ulcer
Smokers ≥ 10 cigarettes per day
Alcohol consumers ≥ 2 units per day
ns: no significant
Inclusion and flow of patients Figure 1
Inclusion and flow of patients. ITT: Intention to Treat. 
PP: Per Protocol.
  
N= 102 patients 
N= 99 patients 
Excluded  3 (Cronic Renal Faillure, 
Allergy  to penicillin, and prior 
treatment with bismuth) 
QT: N= 54 patients  OAR: N= 45 patients  Analysis by ITT 
Randomisation 
Withdrawn 
because of 
adverse affects: 6
Withdrawn 
because  of loss 
of follow up: 2 
N = 48 patients  N =  43 patients Analysis PP BMC Gastroenterology 2007, 7:31 http://www.biomedcentral.com/1471-230X/7/31
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but is uncomfortable to administer, because of the large
number of pills required; moreover, it provokes side
effects that have a negative influence on completion of the
regimen, in normal clinical practice [8]. For these reasons,
many attempts have been made to find alternative treat-
ment regimens that do not present the above problems.
Most such options are based on alternative antibiotics,
because the repetition of treatment cycles based on the
same antibiotics, especially clarithromycin and/or metro-
nidazole, has no possibility whatever of success [25].
In preliminary studies, rifabutin-based therapy had good
results in patients with one or more failed attempts at
eradication, both for patients who are sensitive to antibi-
otics and for those who have developed secondary resist-
ance to clarithromycin and metronidazole as a result of
previous treatments [16,26]. In such studies, the antibi-
otic association most often used is rifabutin 300 mg/day
and amoxicillin (1 gr/12 h), although tests have also been
made with levofloxacin [27].
The present study describes the first clinical trial designed
to compare a rifabutin-based treatment, as a second-line
rescue treatment, with quadruple therapy, which is the
standard recommended. The previous results obtained
with rifabutin-based therapy had been very promising,
with eradication rates of 82–91% [10,16,19,26,27]. How-
ever, our clinical study does not corroborate the above
eradication rates and was found to be less effective than
the quadruple therapy. The latter, on the other hand, in
our series achieved a success rate similar to that found by
other authors [24].
The eradication rate obtained with our rifabutin-based
regimen is one of the lowest published to date. In the first
trial reported, Perri et al. [16] obtained an effectiveness of
80% with a regimen similar to ours, surpassing the 66%
obtained with the quadruple therapy. Perhaps the differ-
ent duration of the treatment implemented (10 days) may
partially explain the difference in the results achieved.
Other authors, however, have published similar results
with rifabutin-based therapy for seven days: Bock [10]
reported an efficacy of 71% in a non-comparative pro-
spective study, in combination with amoxicillin and pan-
toprazole. Longer treatment periods, nevertheless, are not
reported to improve success rates: Gisbert [19] obtained
an eradication rate of 79% in a series limited to 14 cases,
as a third-line rescue treatment, in which the regimen was
administered for two weeks. Torachio [26] published a
study of a 10 day regimen with amoxicillin and pantopra-
zole, applied only to patients with resistance to clarithro-
mycin and metronidazole (whether primary or induced
by previous eradication treatment). An eradication rate of
87% was achieved among the patients who had not been
treated previously and one of 78.5% among those with a
history of failed prior eradication. Recently Borody [28]
Table 3: Side effects in each treatment group.
QT OAR
Total patients 35 (64%) * 20 (44%) *
Dyspepsia
+1 7 8
+++ 1 1
Taste-sensation alteration
+1 2 5
+++ 2
Dizziness
+1 3 4
+++ 1
Diarrhoea
+1 0 6
+++ 1
Nausea/Vomiting
+1 0 5
+++ 3 1
Loss of appetite
+9 6
+++ 2
Cephalea
+8 6
+++ 1 1
Odynophagia
+ 4 (2 candidiasis)
+++
Asthenia/tiredness
+2 3
+++
Total episodes 85 43
Total episodes +++ 11 3
* p 0.042
+: : mild/moderate
+++: : severe
Table 2: Eradication rates of the study population.
Intention to Treat Per Protocol
UBT QT OAR CI 95% QT OAR CI 95%
Negative 38 (70.4%) 20 (40.4%) p = 0.009 37 (77.1%) 20 (46.5%) p = 0.003
Positive 16 (29.6%) 25 (55.6%) 11 (22.9%) 23 (53.5%)
N5 4 4 5 OR 1.58 (1.1–2.29) 48* 43 OR 1.65 (1.1–2.36)
* One patient achieved eradication without having completed the treatment programmeBMC Gastroenterology 2007, 7:31 http://www.biomedcentral.com/1471-230X/7/31
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has reported an eradication rate of 96.6% with a lower
dose of rifabutin (150 mg per day) and an increase in the
dose of amoxicillyn (1.5 gr. tid) and PPI's (pantoprazole
80 mg tid) for 12 days.
Associated with antibiotics other than amoxicillin, Wong
[27] published a comparative study with quadruple ther-
apy applied to patients with one or more previous
attempts at eradication, associating rifabutin (300 mg
day) with levofloxacin (500 mg day); this also gave good
results (91%, versus 90% with the quadruple therapy). In
this line, levofloxacin-based triple therapy is a novel and
promising alternative that seems to offer advantages over
quadruple therapy [29].
To date, only two studies have described an eradication
rate comparable to ours. Quasim [30], in a series of 34
patients included prospectively after two failures,
obtained eradication in only 38% of the cases, and the
second one, reported by Gisbert (31), achieved -with a
rifabutin-based third line therapy- only an eradication
rate of 44%. These studies, together with ours, are the only
ones to obtain such a disappointing outcome.
Therefore, we are faced with the first clinical trial to obtain
unsatisfactory results using a rifabutin-based therapy as
second line treatment. We can find no reasonable expla-
nation for the results obtained. In the randomisation of
our patients, the group treated with the quadruple therapy
included more ulcerous patients than did the rifabutin
group. Patients with a gastroduodenal ulcer seemed to
respond better to the eradication treatment than did those
with chronic gastritis [32]. This might be an explanation
but our patients with a gastroduodenal ulcer had a
response rate (56.8%) similar to that of the non-ulcerous
ones (57.7%), and so this bias in the randomisation does
not seem to have influenced the results obtained.
A priori, nor should the use of amoxicillin in this regimen
have had a negative impact, as a failed eradication treat-
ment does not increase the risk of secondary resistance to
this antibiotic. Not having performed an antibiogram
study before inclusion of the patients might represent a
limitation of the present study, but it seems to have been
proved that resistance to clarithromycin and metronida-
zole does not influence the effectiveness of rifabutin-
based treatments [16,26,27], and primary resistance to
rifabutin is minimal. Moreover, amoxicillin presents a
very low rate of primary resistance in our geographical
area [33].
One possible explanation for our results, compared with
those of other authors, would be the duration of the treat-
ment. Perhaps 7 days is not sufficient for a rifabutin-based
therapy. Nevertheless, our study was designed for a simi-
lar duration in both groups, and guidelines recommended
quadruple-based therapy for seven days [1]. Other possi-
ble explanations might be related to differences obtained
in different geographical areas, as recently reported by
Gisbert [31] in a study conducted in Spain.
The most plausible explanation, nevertheless, would be
the amount of drug dose that was administered. As
Borody reported recently [28], a course of higher doses of
amoxicillin (1 gr or 1.5 gr tid) and pantoprazole (80 mg
tid) for 12 days, even with low dose of rifabutin (150 mg
daily), was well-tolerated and proved to be highly effec-
tive as a rescue therapy for patients having failed previous
treatment. Therefore standard dose of amoxicillin (1gr
bid) and PPI's (omeprazole 20 mg bid) might not be suf-
ficient as a rescue therapy, and a better dosage should be
sought in future comparative studies.
As is the case in other series that have been described, we
found that quadruple therapy frequently provokes side
effects that produce a reduction in the fulfilment of the
therapy (11% of the patients included in the quadruple
therapy regimen did not complete the recommended pro-
gramme). Of the total of 14 events classified as serious or
acute, most of them (11 events) corresponded to the
quadruple therapy regimen. The rifabutin treatment, on
the other hand, was well tolerated, and its side effects were
mainly classified as mild, and had no consequences on
the final rate of fulfilment of the treatment programme.
Conclusion
In summary, in the present study a rifabutin-based ther-
apy, associated to standard dose of amoxicillin and ome-
prazole applied for 7 days was not found to be effective as
a second line rescue treatment against HP infection. The
difficulty in administration and the frequency of side
effects associated with quadruple therapy treatment
underline the need to search for alternative options, with
a different dose of rifabutin-based triple therapy or with
alternative antibiotics which should be better tolerated,
easier to administer and which match or improve upon
the effectiveness achieved with this reference regimen.
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